Guardian Pharmacy ServicesGRDN
Recorded

Guardian Pharmacy Services 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration38 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

I will now hand the call over to Ashley Stockton, Investor Relations. Please go ahead. Good afternoon.

Ashley StocktonVP of Investor Relations

Thank you for participating in today's conference call. This is Ashley Stockton, Vice President, Investor Relations for Guardian Pharmacy Services. I am joined on today's call by Fred Burke, President and Chief Executive Officer, David Morris, Chief Operating Officer, and Will Mudd, Chief Financial Officer. After market closed today, Guardian posted its financial results for the quarter ended September 30, 2026. A copy of the press release is available on the company's investor relations website. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from our expectations.

Ashley StocktonVP of Investor Relations

We encourage you to review the information in today's press release and quarterly report on Form 10-Q, as well as the specific risk factors and uncertainties discussed in our annual report on Form 10-K. We do not undertake any duty to update any forward-looking statements, which speak only as of the date they are made. On today's call, we will also use certain non-GAAP financial measures when discussing the company's financial performance and condition. You can find additional information on these non-GAAP measures and reconciliations to their most directly comparable GAAP financial measures in today's press release, which again is available on our investor relations website. Now, I will turn it over to Fred for high-level commentary.

Fred BurkePresident and CEO

Thank you, Ashley, and good afternoon, everyone. We are extremely pleased with our performance this year and the momentum we are seeing across the business. Our results reflect the strength of the Guardian model, the dedication of our teams, and growing demand for high-quality pharmacy services in the long-term care setting. Given our performance year to date, we are raising our full-year guidance, which Will will discuss in more detail. Before I hand it over to David on operations, I would like to take a few minutes to discuss the broader economic environment, industry fundamentals, and how Guardian is positioned for continued growth. Looking across the broader economy, affordability, higher interest rates, and elevated operating costs all remain concerns. We believe the characteristics of the markets we serve and our business model help insulate Guardian from many of these issues.

Fred BurkePresident and CEO

First, on affordability, it's well-documented that those 75 and over are among the wealthiest segment of the population. We believe this provides an important foundation for long-term demand for private pay assisted living, which represents approximately 70% of the residents we serve. Second, on interest rates, our debt-free balance sheet eliminates direct exposure to higher borrowing costs, while our cash generation has allowed us to fund our typical pace of market expansion without relying on external financing. Finally, our business is delivery-intensive, making fuel an important operating expense, which unfortunately remains elevated. However, as we stated last quarter, our full-year guidance already assumes these higher costs will persist through the remainder of the year. Beyond these macro considerations, conditions across senior housing remain favorable and reinforce the value of Guardian's service model.

Fred BurkePresident and CEO

Assisted living occupancy continues to improve, reaching 89% in the third quarter, according to NIC MAP data, and is expected to continue to climb. At the same time, resident acuity remains elevated, and labor challenges continue to pressure facility operators. As occupancy approaches historical highs and residents' care needs become more complex, operators increasingly need a sophisticated pharmacy partner like Guardian that can manage higher prescription volumes, support complex medication regimens, and invest in the capabilities needed to meet these evolving demands. While rising occupancy provides a modest tailwind for the long-term care pharmacy industry overall, it is important to emphasize that Guardian's growth is not dependent on this trend. With approximately 14% market share, we have substantial runway for growth through new facility wins and expansion into new markets. These opportunities remain firmly intact, even if industry occupancy eventually reaches maximum capacity.

Fred BurkePresident and CEO

At the heart of Guardian's strategy is our commitment to delivering exceptional, high-touch pharmacy services to benefit the residents and facilities we serve. To sustain best-in-class service levels, it is imperative that we are appropriately compensated for the value our services provide in supporting better clinical outcomes and helping bend the cost curve in long-term care. Today, generics account for over 90% of our prescription volume and generate the vast majority of our gross profit. Accordingly, we are advancing a reimbursement model that better compensates us for the services we provide and places greater emphasis on our generic portfolio. This shift represents a meaningful evolution in our approach, one that we are helping to pioneer alongside our payor partners, who increasingly recognize the need for greater transparency. Ultimately, we believe this approach will serve to de-risk our business model and enhance our longer-term stability.

Fred BurkePresident and CEO

Taken together, favorable industry fundamentals, substantial market share opportunity, and our differentiated service model should position Guardian exceptionally well for the future. Coupled with our efforts to strengthen reimbursement economics, consistent cash generation, and our highly liquid balance sheet, I am ever more confident in Guardian's ability to deliver durable growth and shareholder value. With that, I'll turn the call over to David.

David MorrisCOO

Thanks, Fred, and good afternoon, everyone. I'd like to focus on our operational progress, where we made meaningful strides this quarter in expanding our resident base, both through greenfield startups and acquisitions. Our greenfield startup in Lexington, Kentucky, announced last quarter, is now operational. We're also moving forward with plans to further expand our presence in Texas and Alabama, with new locations in Houston and Huntsville, respectively. These additions will mark our second pharmacy location in each state. Our Wellness Concepts acquisition in Grottoes, Virginia, closed in July. While still early, the integration is on track. We also completed the Nautilus asset acquisition late in the quarter, representing a unique opportunity to add scale across our existing pharmacy network. Nautilus previously served assisted living communities across 14 states through a centralized mail order model.

David MorrisCOO

We now have transitioned all of these residents to 18 Guardian pharmacies already operating in their respective markets, providing them access to our locally managed, high-touch pharmacy services. From a financial perspective, this is an attractive asset-light transaction that allows us to leverage existing infrastructure and operating capacity to absorb additional residents with limited incremental investment. As a result, this transaction is immediately accretive after we absorb the cost of onboarding. In October, we added a small pharmacy in Sioux City. Collectively, with our existing pharmacy in that area, it gives us a more significant presence in Northwest Iowa. Lastly, earlier this week, we also completed the acquisition of Van's Institutional Pharmacy, a well-established long-term care pharmacy serving communities across Western Tennessee and Kentucky. This acquisition brings our total pharmacy count to five in Tennessee.

David MorrisCOO

Van's is slightly smaller than our typical acquisition, but it is an excellent cultural and operational fit, having built a reputation for high-quality service over a period of more than 50 years that aligns closely with our commitment to service excellence. Looking ahead, our acquisition pipeline remains active. Additionally, we see significant potential to build greater scale and density in adjacent markets through our contiguous greenfield startups. Maintaining both our organic and inorganic growth requires the right leadership, which is why we established our regional SVP structure earlier this year. This team is already driving greater consistency, accountability, and collaboration across our pharmacy network while preserving the local decision-making and entrepreneurial culture that have long been central to Guardian.

David MorrisCOO

More specifically, we are seeing benefits through increased sharing of best practices, better coordination of sales and account management efforts, and opportunities to improve operating efficiencies, both within individual pharmacies and across regions. This is particularly important as we expand relationships with regional and national customers who rely on Guardian to deliver consistency across multiple states and markets. While our regional leaders play an important role, it's the dedication of our people across the entire organization that makes all this possible. On behalf of our senior management team, I'd like to thank everyone for their hard work and commitment to the customers and residents we serve. Our people remain the foundation of Guardian's success. With that, I'll turn the call over to Will for a more detailed review of our financial performance and updated outlook.

Will MuddCFO

Thank you, David, and good afternoon, everyone. As David mentioned, we delivered another strong quarter with solid growth in residents served, prescription volumes, and Adjusted EBITDA. We ended the quarter serving approximately 218,000 residents, representing high single-digit growth compared with the prior year period. Alongside this growth, prescription volumes increased 10% year-over-year. Reported revenue was $371 million, compared with $377 million in the prior year period, representing a reported decline of 1.7%. Absent the impact of IRA-related drug price reductions that took effect earlier this year, revenues would have increased high single digits in line with what we guided to last quarter, mostly reflecting organic growth. Note, Wellness Concepts, our primary acquisition year to date, was on the smaller side, and Nautilus did not meaningfully contribute to this quarter. Gross profit was $85.2 million, up 14% year-over-year. Gross margin was also up sequentially to 23%.

Will MuddCFO

Revenue and margins continue to benefit from improved reimbursement, ongoing purchasing initiatives, plan optimization efforts, and a successful launch to this year's vaccine programs. Adjusted SG&A was $57.4 million, representing 15.5% of revenues. We continue to benefit from operating leverage as our resident base and prescription volumes grow, allowing us to spread our fixed operating costs across a larger base of business. Share-based compensation was close to $2.8 million. Adjusted EBITDA increased 24% year-over-year to $33.9 million. EBITDA margin was 9.1%. Acquisitions and greenfield startups completed since 2024 are collectively contributing positive Adjusted EBITDA, although they dampened our Adjusted EBITDA margin by 44 basis points in the quarter. The effective tax rate came in at 26%. Net income was $19 million, up from $9.6 million in the year-ago quarter.

Will MuddCFO

Given our strong year-to-date performance and current expectations for the fourth quarter, we are raising our full year 2026 guidance. We now expect revenue in the range of $1.44 billion-$1.46 billion, up from $1.43 billion-$1.45 billion. Adjusted EBITDA is now expected in the range of $136 million-$138 million, up from $129 million-$131 million. Our updated outlook reflects our stronger-than-expected third quarter performance, various market expansion initiatives David laid out, and the continuation of improved reimbursement and other strong operating trends into the fourth quarter. As in the past, our guidance does not assume any additional acquisitions beyond those already completed. Turning to our balance sheet, we ended the quarter with approximately $120 million in cash and no debt. Our capital allocation priorities remain focused on supporting long-term profitable growth while maintaining the financial discipline that has been a hallmark of Guardian's strategy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day